Читать книгу The SAGE Encyclopedia of Stem Cell Research - Группа авторов - Страница 377

Hematopoietic stem cell transplant (HSCT) is currently considered the standard approach for the treatment of various blood deficiencies and disorders. These results stem from different clinical trials that examined the effectiveness and safety of stem cells derived from cord blood, bone marrow, and peripheral blood. The earliest efforts in using hematopoietic stem cells were conducted in 1968, which generated additional information in understanding the composition of these stem cell sources. For example, research studies 40 years ago showed that the density of stem cells in peripheral blood was relatively low. This finding fueled investigations into methods of enriching peripheral blood with stem cells using various techniques such as growth factors or chemotherapeutic reagents.

Thirty years ago, research showed that cord blood was another resource for stem cells that could be employed in allogeneic HSCT using a relatively lower cell density than that using peripheral blood or bone marrow. To date, stem cells from bone marrow and peripheral blood have been extensively used in HSCT.